Prevalence of Dyschromatopsia in Glaucoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01994564|
Recruitment Status : Withdrawn
First Posted : November 26, 2013
Last Update Posted : November 26, 2013
Glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons (retinal nerve fibers). Retinal nerve fibers are ordered in a special manner when they enter the optic nerve. Hence, damage to the retinal nerve fibers by glaucoma results in visual field defects at certain locations. Furthermore, the retinal nerve fiber layers from different receptors for different colors are ordered in a special manner as well. Thus, it is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia).
At the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or only in end-stage glaucoma.
By testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma and in different stages of the disease will be investigated.
|Condition or disease|
|Open Angle Glaucoma|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Prevalence of Dyschromatopsia in Glaucoma Patients|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||January 2014|
- Result from Ishihara Test [ Time Frame: Visit 1 ]Color vision will be tested once by Ishihara plates. Both eyes will be tested separately.
- Glaucoma stage [ Time Frame: Visit 1 ]Visual field will be tested with 30-2 Humphrey visual field full threshold test. Visual field defects will we graded following the Hodapp-Anderson-Parrish Scale (Hodapp E, Parrish RK, Anderson DR. Classification of Defects in Clinical Decisions in Glaucoma. St. Louis: Mosby, 1993:52-61).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01994564
|United States, Massachusetts|
|Massachusetts Eye & Ear Infirmary|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Douglas J. Rhee, M.D.||Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, MA, US|